Zacks Research Analysts Raise Earnings Estimates for SRPT

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Research analysts at Zacks Research boosted their Q2 2025 earnings per share (EPS) estimates for shares of Sarepta Therapeutics in a report released on Monday, October 21st. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will earn $2.09 per share for the quarter, up from their previous estimate of $2.08. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $1.45 per share. Zacks Research also issued estimates for Sarepta Therapeutics’ Q3 2025 earnings at $2.10 EPS, Q4 2025 earnings at $2.18 EPS, FY2025 earnings at $8.17 EPS and Q1 2026 earnings at $2.80 EPS.

Several other research firms also recently commented on SRPT. Barclays decreased their price objective on Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $205.00 price target on shares of Sarepta Therapeutics in a research note on Monday, October 14th. Cantor Fitzgerald reissued a “neutral” rating and set a $152.00 price objective on shares of Sarepta Therapeutics in a research note on Friday, September 20th. Evercore ISI upgraded shares of Sarepta Therapeutics from an “in-line” rating to an “outperform” rating and cut their target price for the stock from $185.00 to $179.00 in a report on Thursday, August 8th. Finally, UBS Group upped their price target on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a report on Tuesday, September 17th. Two investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $182.95.

Sarepta Therapeutics Price Performance

Shares of NASDAQ:SRPT opened at $128.42 on Wednesday. The company’s fifty day moving average is $128.87 and its 200 day moving average is $132.42. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05. Sarepta Therapeutics has a 52 week low of $55.25 and a 52 week high of $173.25. The stock has a market cap of $12.14 billion, a PE ratio of 1,167.45 and a beta of 0.82.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The business had revenue of $362.90 million for the quarter, compared to analysts’ expectations of $394.38 million. During the same period last year, the business earned ($0.27) earnings per share. The business’s quarterly revenue was up 38.9% on a year-over-year basis.

Insider Activity

In related news, CFO Ian Michael Estepan sold 5,985 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at $4,662,822.56. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the sale, the chief financial officer now owns 33,946 shares of the company’s stock, valued at $4,662,822.56. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Michael Andrew Chambers acquired 37,038 shares of the business’s stock in a transaction on Friday, August 16th. The stock was acquired at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the acquisition, the director now owns 284,034 shares of the company’s stock, valued at approximately $38,003,749.20. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. 7.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in SRPT. Capital International Investors increased its holdings in shares of Sarepta Therapeutics by 1.6% during the first quarter. Capital International Investors now owns 4,817,517 shares of the biotechnology company’s stock valued at $623,676,000 after acquiring an additional 76,032 shares in the last quarter. Farallon Capital Management LLC grew its position in Sarepta Therapeutics by 102.8% during the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock valued at $317,630,000 after purchasing an additional 1,243,427 shares during the last quarter. Thrivent Financial for Lutherans increased its stake in Sarepta Therapeutics by 6.3% during the 2nd quarter. Thrivent Financial for Lutherans now owns 644,675 shares of the biotechnology company’s stock valued at $101,858,000 after purchasing an additional 37,940 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its holdings in Sarepta Therapeutics by 26.3% in the first quarter. Jacobs Levy Equity Management Inc. now owns 579,637 shares of the biotechnology company’s stock worth $75,040,000 after buying an additional 120,535 shares during the last quarter. Finally, Fiera Capital Corp lifted its stake in shares of Sarepta Therapeutics by 4.3% in the second quarter. Fiera Capital Corp now owns 382,645 shares of the biotechnology company’s stock worth $60,458,000 after buying an additional 15,606 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.